Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

SML2902

Sigma-Aldrich

LP-922056

≥98% (HPLC)

Synonym(s):

2-((6-Chloro-7-cyclopropylthieno[3,2-d]pyrimidin-4-yl)thio)acetic acid, LP 922056

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C11H9ClN2O2S2
CAS Number:
1365060-22-5
Molecular Weight:
300.78
MDL number:
MFCD22572369
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

−20°C

SMILES string

[s]1c2c(ncnc2SCC(=O)O)c(c1Cl)C3CC3

InChI

1S/C11H9ClN2O2S2/c12-10-7(5-1-2-5)8-9(18-10)11(14-4-13-8)17-3-6(15)16/h4-5H,1-3H2,(H,15,16)

InChI key

LJYRIWUQISYYHA-UHFFFAOYSA-N

Biochem/physiol Actions

LP-922056 is an orally active, potent and selective NOTUM pectinacetylesterase inhibitor that activates Wnt signaling. LP-922056 stimulates endocortical bone formation in rodents and in humanized NOTUM mouse line.
orally active, potent and selective NOTUM pectinacetylesterase inhibitor that activates Wnt signaling and stimulates bone formation

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000149050
0000149050
0000109853
0000109852
0000106374

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

James E Tarver et al.
Bioorganic & medicinal chemistry letters, 26(6), 1525-1528 (2016-02-22)
A group of small molecule thienopyrimidine inhibitors of Notum Pectinacetylesterase are described. We explored both 2-((5,6-thieno[2,3-d]pyrimidin-4-yl)thio)acetic acids and 2-((6,7-thieno[3,2-d]pyrimidin-4-yl)thio)acetic acids. In both series, highly potent, orally active Notum Pectinacetylesterase inhibitors were identified.
Robert Brommage et al.
Bone research, 7, 2-2 (2019-01-10)
The disability, mortality and costs caused by non-vertebral osteoporotic fractures are enormous. Existing osteoporosis therapies are highly effective at reducing vertebral but not non-vertebral fractures. Cortical bone is a major determinant of non-vertebral bone strength. To identify novel osteoporosis drug

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service